GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (FRA:TAL) » Definitions » 3-Year EBITDA Growth Rate

Taro Pharmaceutical Industries (FRA:TAL) 3-Year EBITDA Growth Rate : -38.80% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Taro Pharmaceutical Industries 3-Year EBITDA Growth Rate?

Taro Pharmaceutical Industries's EBITDA per Share for the three months ended in Dec. 2023 was €0.57.

During the past 12 months, Taro Pharmaceutical Industries's average EBITDA Per Share Growth Rate was 527.70% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -38.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Taro Pharmaceutical Industries was 63.70% per year. The lowest was -38.80% per year. And the median was 23.05% per year.


Competitive Comparison of Taro Pharmaceutical Industries's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taro Pharmaceutical Industries's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's 3-Year EBITDA Growth Rate falls into.



Taro Pharmaceutical Industries 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Taro Pharmaceutical Industries  (FRA:TAL) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Taro Pharmaceutical Industries 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (FRA:TAL) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.

Taro Pharmaceutical Industries (FRA:TAL) Headlines

From GuruFocus

TAL Education Group Files Its Annual Report on Form 20-F

By PRNewswire PRNewswire 05-31-2023